Levels of Matrix Metalloproteinase-8 After Intrapocket Treatment in Moderate Periodontitis Patients.

• Status: Completed
• Trial end date: 2020-10-14
• Target enrollment: 0
• Participant gender: All

Summary

Using local delivery drugs as adjunctive to scaling and root planing and evaluating gingival crevicular fluid (GCF) biological molecular markers (MMP-8).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alexandria University

Criteria

Inclusion Criteria:

1. Patients of both sexes having moderate periodontitis (stage II), CAL 3-4mm.

2. Patients' age between 25 and 45 years old.

3. Systemically healthy patients.

4. No history of periodontal therapy (surgical and non-surgical) or taken any antibiotic therapy for the past six months.

Exclusion Criteria:

1. History of smoking.

2. Patients having previous adverse reaction to the products (or similar products) used in this study.

3. Grade C category that has rapid rate of progression.

4. Pregnant and lactating women.